American Academy of Dermatology

At AAD 2026, Christopher Bunick, MD, PhD, and Patrick Burnett, MD, PhD, discuss late-breaking data of roflumilast cream's improvements in infants with AD.

Pelage’s PP405 novel topical reawakens dormant follicle stem cells, showing signs of terminal regrowth and fueling late-stage alopecia research.

Late-breaking phase 2 findings presented at AAD show nemolizumab achieved high EASI-90 rates and rapid itch relief in pediatric patients with atopic dermatitis.

Catch up on coverage from the first day of the 2026 American Academy of Dermatology Annual Meeting held in Denver, Colorado.

Nicole Negbenebor, MD, highlights the clinical and professional impact of community-driven education and evidence-based focus in skin of color dermatology.

Christopher Bunick, MD, PhD, interviews medical student Sabine Obagi on the value of conference participation, mentorship, and early exposure for aspiring dermatology clinicians at AAD 2026.

Melanoma cases keep rising, but AI-aided screening, gene profiling, and newer immunotherapies boost early diagnosis and long-term survival, according to Darrell Rigel, MD, MS.

This year’s AAD poster awards highlight studies advancing skin cancer prevention, inflammatory disease management, and complex dermatology care.

BE HEARD extension data underscore the importance of early diagnosis and treatment initiation to optimize long-term outcomes in hidradenitis suppurativa.

With 80% of trial participants being children, this analysis provides some of the most robust early-response data available for a non-steroidal topical in pediatric AD.

Read more on how to navigate all the opportunities at this year’s AAD meeting, which starts today in Denver, Colorado.

The GLODERM Pre–AAD meeting emphasized that global skin health progress now depends on translating policy into scalable, equitable care delivery.

At the pre-AAD meeting, Regina Benjamin, MD, MBA, discussed the role of clinicians as leaders in addressing social determinants of health, emphasizing prevention, education, and culturally responsive care.

These leaders are shaping the future of dermatology through their clinical expertise, research, and educational presentations.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Discover how upadacitinib outperforms dupilumab in providing rapid itch relief for moderate-to-severe atopic dermatitis in a recent AAD study.

Dermatology undergoes rapid transformation with new therapies, but faces challenges in payment reform, certification awareness, and balancing technology with patient care.

Paller discusses the promising phase 3 trial SELVA trial results for Qtorin 3.9% rapamycin gel, an investigative treatment for microcystic lymphatic malformations.

From our April issue: Unlock exclusive AAD 2025 insights from top dermatology experts—what you missed and what’s next.

Tapinarof offers sustained relief for atopic dermatitis, enabling treatment-free periods and long-term disease control—even in young children.

Asha Patel Shah, MD, MBA, FAAD, discusses recent research on retinol and retinoid bioactivity when layered with moisturizers highlighted at AAD 2025.

Discover the latest research from the AAD poster hall, compiled in one place for dermatology professionals.

Explore a comprehensive roundup of the most important AAD late breakers, all in one place – key insights from the latest dermatology research.

Christopher B. Zachary, MBBS, MRCP, FRCP, shares insights in apoptosis-based skin care treatment.

Catch up on all coverage from the 2025 American Academy of Dermatology Annual Meeting held in Orlando, Florida, March 7-11.

Christopher Bunick, MD, PhD, shares concluding remarks with colleagues at AAD 2025.

Karl Yen of Sanofi discussed the role of amlitelimab in AD following sustained results and a promising safety profile presented in data at AAD.

Novartis highlighted key findings at AAD and AAAAI, showcasing Cosentyx's flexible dosing for hidradenitis suppurativa and remibrutinib’s efficacy for chronic spontaneous urticaria.

Elizabeth Berry, MD, FAAD, reviewed dysplastic nevi as risk markers and highlighted the need for more data on severe cases at AAD 2025.